Format

Send to:

Choose Destination
See comment in PubMed Commons below
Am J Psychiatry. 2002 Sep;159(9):1596-8.

Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia.

Author information

  • 1Department of Psychiatry, University of Stellenbosch, Tygerberg, Cape Town, South Africa. rae@sun.ac.za

Abstract

OBJECTIVE:

The study investigated the efficacy and tolerability of ethyl-eicosapentaenoic acid (E-EPA) as add-on treatment in chronic, severe schizophrenia.

METHOD:

A randomized, parallel-group, double-blind, placebo-controlled, fixed-dose, add-on study was conducted over 12 weeks. Forty patients with persistent symptoms after at least 6 months of stable antipsychotic treatment received E-EPA or placebo, in addition to their existing treatment.

RESULTS:

At 12 weeks, the E-EPA group had significantly greater reduction of Positive and Negative Syndrome Scale total scores and of dyskinesia scores than the placebo group.

CONCLUSIONS:

EPA may be an effective and well-tolerated add-on treatment in schizophrenia.

PMID:
12202284
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk